Abstract: There is provided, inter alia, an aqueous solution composition of pH in the range 4.0-7.5 comprising: a peptide therapeutic agent; optionally one or more buffers being substances having at least one ionisable group with a pK a in the range 3.0 to 8.5 and which pk a is within 2 pH units of the pH of the composition; and a stabilizer; wherein the peptide therapeutic agent does not contain ionisable groups with pk a in the range 3.0 to 8.5, and wherein the buffers are present in the composition at a total concentration of 0-5 mM.

Abstract: The present application relates to aqueous solution compositions of engineered dimeric proteins comprising monomers that comprise at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide, at low buffer concentrations and low ionic strength and containing a neutral amino acid. The aqueous solution compositions increase the stability of the an Fc domain in aqueous solution compositions, and in particular increase the stability of an engineered dimeric protein.

Abstract: The present application relates to aqueous solution compositions of engineered dimeric proteins comprising monomers that comprise at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide, at low buffer concentrations and low ionic strength and containing a neutral amino acid. The aqueous solution compositions increase the stability of the an Fc domain in aqueous solution compositions, and in particular increase the stability of an engineered dimeric protein.

Abstract: The invention provides inter alia an aqueous solution composition of pH in the range 4.0-6.0 comprising: —terlipressin or a salt thereof; —optionally one or more buffers being substances having at least one ionisable group with a pKa in the range 3.0 to 7.0 and which pKa is within 1 pH unit of the pH of the composition; —optionally an amino acid; and—optionally a tonicity modifier wherein the buffers are present in the composition at a total concentration of 0-5 mM.

Abstract: There is provided, inter alia, an aqueous solution composition of pH in the range 4.0-7.5 comprising: a peptide therapeutic agent; optionally one or more buffers being substances having at least one ionisable group with a pKa in the range 3.0 to 8.5 and which pKa is within 2 pH units of the pH of the composition; and a stabilizer; wherein the peptide therapeutic agent does not contain ionisable groups with pKa in the range 3.0 to 8.5, and wherein the buffers are present in the composition at a total concentration of 0-5 mM.

Abstract: A disclosed process includes steps of heating a foamed material by irradiation with near infrared radiation having a wavelength between 0.78 and 1.40 ?m to form a heated material, forming the heated material with a forming tool to obtain a formed material, and cooling the formed material and demolding to obtain a final workpiece. The foamed material may be constructed as a composite ply construction including an outer material and a foamed core between the outer material. The foamed material may contain a poly(meth)acrylimde, a polypropylene or a highly-crosslinked polyurethane.

Abstract: A disclosed process includes steps of heating a foamed material by irradiation with near infrared radiation having a wavelength between 0.78 and 1.40 ?m to form a heated material, forming the heated material with a forming tool to obtain a formed material, and cooling the formed material and demolding to obtain a final workpiece. The foamed material may be constructed as a composite ply construction including an outer material and a foamed core between the outer material. The foamed material may contain a poly(meth)acrylimde, a polypropylene or a highly-crosslinked polyurethane.